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A significant proportion of men with rising prostate-specific antigen
(PSA) levels after radical prostatectomy (RP) fail prostate fossa (PF)
salvage radiation treatment (SRT). This study was done to assess
the ability of 18F-fluoromethylcholine (18F-FCH) PET/CT (hereafter
referred to as 18F-FCH), 68Ga-HBED-CC PSMA-11 PET/CT (hereaf-
ter referred to as PSMA), and pelvic multiparametric MRI (hereafter
referred to as pelvic MRI) to identify men who will best benefit from
SRT. Methods: Prospective, multisite imaging studies were carried
out in men who had rising PSA levels after RP, high-risk features,
and negative/equivocal conventional imaging results and who were
being considered for SRT. 18F-FCH (91/91), pelvic MRI (88/91), and
PSMA (31/91) (Australia) were all performed within 2 wk. Imaging
was interpreted by experienced local/central interpreters who were
masked with regard to other imaging results, with consensus being
reached for discordant interpretations. Expected management was
documented before and after imaging, and data about all treat-
ments and PSA levels were collected for 3 y. The treatment re-
sponse to SRT was defined as a reduction in PSA levels of .50%
without androgen deprivation therapy. Results: The median Glea-
son score, PSA level at imaging, and PSA doubling time were 8,
0.42 (interquartile range, 0.29–0.93) ng/mL, and 5.0 (interquartile
range, 3.3–7.6) months. Recurrent prostate cancer was detected
in 28% (25/88) by pelvic MRI, 32% (29/91) by 18F-FCH, and 42%
(13/31) by PSMA. This recurrence was found within the PF in 21.5%
(19/88), 13% (12/91), and 19% (6/31) and at sites outside the PF
(extra-PF) in 8% (7/88), 19% (17/91), and 32% (10/31) by MRI, 18F-
FCH, and PSMA, respectively (P , 0.004). A total of 94% (16/17) of
extra-PF sites on 18F-FCH were within the pelvic MRI field. Intra-
pelvic extra-PF disease was detected in 90% (9/10) by PSMA and in
31% (5/16) by MRI. 18F-FCH changed management in 46% (42/91),
and MRI changed management in 24% (21/88). PSMA provided
additional management changes over 18F-FCH in 23% (7/31). The
treatment response to SRT was higher in men with negative results
or disease confined to the PF than in men with extra-PF disease
(18F-FCH 73% [32/44] versus 33% [3/9] [P , 0.02], pelvic MRI 70%
[32/46] versus 50% [2/4] [P was not significant], and PSMA 88% [7/
8] versus 14% [1/7] [P , 0.005]). Men with negative imaging results
(MRI, 18F-FCH, or PSMA) had high (78%) SRT response rates. Con-
clusion: 18F-FCH and PSMA had high detection rates for extra-PF
disease in men with negative/equivocal conventional imaging re-
sults and rising PSA levels after RP. These findings affected man-
agement and treatment responses, suggesting an important role for
PET in triaging men being considered for curative SRT.
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Approximately 20%–50% of pT2 to pT3, node-negative pros-
tate cancer patients experience biochemical recurrence (BCR) af-
ter radical prostatectomy (RP). Salvage radiation treatment (SRT)
is the only potentially curative treatment option for these patients.
The 5-y progression-free survival rate after SRT is approximately
50%, varying from 71% in men with preradiotherapy prostate-
specific antigen (PSA) levels of 0.2 ng/mL to 12% in men with
high-risk features (1–3). Because SRT generally targets disease in
the prostate fossa (PF) and may have adverse effects on quality
of life, patients with disease outside the PF (extra-PF) ideally
should be spared futile salvage radiotherapy to the PF only or
considered for treatment intensification (addition of pelvic nodal
radiotherapy to fossa irradiation or androgen deprivation ther-
apy [ADT]). SRT is most effective at low PSA levels (,1.0–2.0
ng/mL) (3,4), at which conventional imaging (bone scan and CT) is
insensitive.
The aim of this study was to assess the ability of 18F-fluorome-
thylcholine (18F-FCH) PET/CT (hereafter referred to as 18F-FCH),
pelvic multiparametric MRI (hereafter referred to as pelvic MRI),
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and 68Ga-HBED-CC PSMA-11 PET/CT (hereafter referred to as
PSMA) to identify men who have BCR after RP, negative conventional
imaging results, and high-risk clinical features and who will best
benefit from SRT.
MATERIALS AND METHODS
Men who had biochemical failure after RP and high-risk features
and who were being considered for SRT were prospectively recruited
at 8 sites across Australia, Canada, and the United Kingdom. The
study protocol was approved by all institutional ethics boards
(www.clinicaltrials.gov NCT02131649). Eligible consenting men had
biopsy-confirmed prostate cancer, prior RP (pT1–pT3, N0, or Nx),
and rising PSA levels (3 consecutive rises documented a minimum of
2 wk apart, with PSA levels of greater than or equal to 0.2 ng/mL), and
at least 1 high-risk feature (PSA level of .1.0 ng/mL,$pT3b, Gleason
score of .7, or PSA doubling time of #10 mo). Diagnostic CT and
bone scans within 12 wk of enrollment were negative or equivocal for
metastases, with planned management before enrollment of standard
fossa SRT with curative intent. A total of 91 men satisfied screening
criteria and were enrolled in the study between July 2014 and January
2017. Enrolled men underwent both 18F-FCH and pelvic MRI within a
2-wk period, with men in Australia undergoing an additional PSMA
study within the same time frame as part of the study protocol. Three of
91 men failed to complete the pelvic MRI component because of claus-
trophobia. All 91 men underwent 18F-FCH imaging, 88 of 91 completed
pelvic MRI, and 31 of 91 completed PSMA imaging.
Radiopharmacy and PET Acquisition
Radiopharmacy production of 18F-FCH and 68Ga-HBED-CC PSMA-
11 (Australian sites only) was undertaken within each participating
institution, which were required to comply with local production and
quality control requirements. Imaging protocols were harmonized
across institutions for each modality. All men underwent immediate
dynamic pelvic imaging (10 min) and then delayed whole-body 18F-
FCH imaging at 60 min after the intravenous administration of 18F-FCH
(3.6 MBq/kg, to a maximum of 400 MBq at the time of injection). A
low-dose, noncontrast CT scan was initially performed for attenuation
correction and image fusion, with coverage from the skull base to the
proximal thighs in the supine position. Initial dynamic scan frames were
acquired over the pelvis at 4 · 30 s, 4 · 1 min, and 2 · 2 min. Sub-
sequently, whole-body PET acquisition was acquired toward the head.
In men undergoing PSMA, imaging from the vertex to the midthighs
was undertaken at least 60 min after the intravenous administration of
68Ga-HBED-CC PSMA-11 (2.0 MBq/kg, to a maximum of 200 MBq at
the time of injection). PET imaging data were stored on a centralized
secure server for central review.
Pelvic MRI Acquisition
Pelvic MRI was performed in accordance with local institutional
protocols but was harmonized to include small–field-of-view, pelvic
T2 axial and coronal sequences, axial pelvic dynamic contrast-enhanced
MRI after the administration of gadolinium-based contrast material, and
axial pelvic diffusion-weighted imaging with b50 and b1000 diffusion
weightings. After acquisition, MRI data were uploaded to a centralized
online secure server and centrally reviewed for quality.
Reporting of Imaging Procedures
After the completion of each imaging procedure, both local and
central interpretations were acquired for each imaging modality. All
PET (18F-FCH and PSMA) interpretations were undertaken by nuclear
medicine physicians who had prostate imaging experience and who
were masked with regard to other imaging results, with consensus being
reached for discordant interpretations between local sites and the central
interpretation site (Peter MacCallum Cancer Centre). MRI was inter-
preted by local MRI specialists, with a central interpretation by an MRI
radiologist who was a prostate specialist and a consensus interpretation
by a second prostate MRI specialist for discordance. 18F-FCH, PSMA,
and pelvic MRI were scored by site of disease (PF, pelvic lymph nodes,
distant lymph nodes, bone, or viscera) with a 4-point certainty score
assigned to each positive finding (definitely negative, probably negative,
probably positive, and definitely positive) (5). Agreement among inter-
preters for the detection of fossa-confined disease and extra-PF disease
was substantial for PSMA (kappa score, 0.83) and fair to good for both
pelvic MRI (kappa score, 0.59) and 18F-FCH (kappa score, 0.61). The
consensus results were used for statistical analysis.
Management Impact Questionnaires
All treating investigators undertook a preimaging management ques-
tionnaire documenting the intended management, including planned
site, fractions and dose of radiotherapy, whether ADT was planned,
and duration of ADT. After the completion of imaging and dissem-
ination of the 18F-FCH report to the investigating clinicians, a ques-
tionnaire providing information on changes in intended management
was completed. A second questionnaire detailing the management
impact of pelvic MRI was completed by treating investigators. For the
subgroup of men undergoing PSMA, a separate questionnaire evaluated
the incremental management impact of PSMA findings over 18F-FCH.
Serial PSA was documented in all men every 3 mo for the first 12 mo
after treatment and then every 6 mo for 3 y. Biopsy results (when avail-
able) and imaging-documented sites of disease progression were also
collated.
Documentation of Treatments Undertaken
All men were being actively considered and were eligible for
standard fossa SRT. Quality control of investigative site SRT plans
was undertaken by expert radiation oncologists appointed by a trial
management committee before commencement of the study through
the completion and central review of a standardized trial PF
radiotherapy case. In accordance with the protocol, men without
disease or with disease confined to the PF on PET imaging were
expected to proceed to SRT. For men in whom extra-PF sites were
identified, the study did not dictate the treatment to be received.
Accordingly, on the basis of clinician preference, some men un-
derwent no treatment, whereas others received conformal or in-
tensity-modulated radiotherapy to the prostate bed (with or without
pelvic lymph nodes), ADT, or a combination of radiotherapy and
ADT. All treatments undertaken—including volume, timing, and frac-
tions of radiotherapy administered, duration and type of systemic ther-
apy, and any biopsies obtained—were documented.
Treatment Response
Treatment response was defined as a drop in PSA levels of greater
than 50% from pretreatment levels in the absence of ADT at the time
of PSA assessment at least 6 mo after treatment. Men who were placed
on ADT as part of their treatment were not included in the assessment
of the initial treatment response, although their PSA levels continued
to be collected for up to 3 y after the commencement of therapy in the
trial. Full assessment of biochemical failure will be undertaken once
the 3-y follow-up is complete (median follow-up, 16.1 mo; interquartile
range, 13.2–25.8 mo).
Composite Reference Standard
In accordance with the study protocol, biopsy of lesions with
positive imaging results was recommended but, given the difficulties
of obtaining biopsies of small lesions in biochemical failure after RP,
was not mandated. A composite reference standard incorporating a
biopsy and a targeted treatment response was applied to all imaging
modalities (Fig. 1). For the composite reference standard, patients who
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received ADT without a biopsy outside of the prostate bed were ex-
cluded. Patients who underwent surveillance without having a biopsy
performed outside of the prostate bed were also excluded. Thus, the
composite reference was based on either a biopsy or a response to SRT
of either the fossa only or the fossa plus regional nodes.
Statistical Analysis
Descriptive statistics were used to summarize baseline character-
istics and outcomes of interest. Fisher exact tests were used to evaluate
differences in proportions between 2 groups of patients, whereas the
McNemar test was used to examine different rates of detection be-
tween imaging modalities within the same patient. The Cohen k
was used to measure interobserver agreement for all modalities. The
Wilcoxon signed rank test was used for nonparametric data to assess
the numbers of lesions detected by different modalities. All tests were
2-sided, and a P value of 0.05 or less was deemed statistically signif-
icant. Diagnostic accuracy was determined using the composite refer-
ence standard described earlier.
RESULTS
Baseline characteristics are summarized in Table 1. A total of
91 men were eligible, consented, and enrolled in this study. All men
were enrolled in the trial between June 2014 and January 2017.
Detection Rates for Recurrent Prostate Cancer
Overall detection rates for recurrent prostate cancer were 28%
(25/88) for pelvic MRI, 32% (29/91) for 18F-FCH, and 42% (13/
31) for PSMA. Pelvic MRI and PSMA had the highest detection
rates for local recurrence (PF)—21.5% (19/88) and 19% (6/31),
respectively—with 13% (12/91) for 18F-FCH (P was not signifi-
cant) (Table 2). Extra-PF sites were identified in 19% (17/91) by
18F-FCH, 8% (7/88) by pelvic MRI, and 32% (10/31) by PSMA
(P , 0.004). The per-patient extra-PF disease identified (all mo-
dalities) was pelvic nodal disease in 82% (14/17), osseous disease
in 12% (2/17), and lung disease in 6% (1/17). For 16 of 17 patients
(94%), extra-PF disease on 18F-FCH was within the field of view
of pelvic MRI.
Among men imaged with 18F-FCH and PSMA, PSMA detected
most (90% [9/10]) of the pelvic extra-PF lesions identified by 18F-
FCH. For men imaged with 18F-FCH and MRI, MRI detected only
5 of 16 pelvic extra-PF sites (31%) identified by 18F-FCH. Of men
with pelvic MRI findings confined to the PF or with negative
scans, 15% (12/81) had additional sites of distant disease detected
on 18F-FCH (P, 0.003). Similarly, in men
with negative scans or PF-confined disease
on 18F-FCH, pelvic MRI demonstrated extra-
PF disease in 3% (2/74) (Table 3). For the 31
men who underwent PSMA imaging, 18F-
FCH and PSMA identified recurrent disease
in 10 (Table 3)—although PSMA identified
36 sites of disease, whereas 18F-FCH identi-
fied 20 (P , 0.02). One of 13 men had an
18F-FCH–positive pelvic lymph node that
was not identified on PSMA and that was
negative on biopsy (18F-FCH false positive),
and 1 of 13 had a PSMA-positive thoracic
spinal lesion that was not identified on 18F-
FCH (PSMA true positive) (Fig. 2).
Reference Standard and
Diagnostic Accuracy
A composite reference standard was
applied to all imaging modalities to determine diagnostic accu-
racy. A total of 68% of the men (62/91) were assessed using the
composite reference standard; 32% (29/91) were excluded be-
cause they did not undergo biopsy and either did not undergo
treatment after imaging or were placed on ADT as part of their
treatment. Overall, 12% of the men (11/91) underwent biopsy of
scan-positive sites of disease. With the reference standard, speci-
ficity was high with all modalities; the sensitivity of the PET agents
was higher than that of MRI in a per-patient analysis (Table 4).
FIGURE 1. Flow chart for determining composite reference standard used in assessment of
diagnostic accuracy for PSMA, 18F-FCH, and pelvic MRI. FN5 false negative; FP5 false positive;




Median age† 64 (59–69) y
Median PSA level at imaging† 0.42 (0.29–0.93) ng/mL





Positive surgical margins 27 (29.7)
Gleason score
6 or 7 60 (66)
8–10 29 (32)
Median mo since RP† 23 (9–46.5)
Treatment received
No treatment administered 19 (21)
Salvage fossa RTX 44 (48)
Fossa 1 pelvic nodal RTX 8 (9)
RTX of fossa/nodes 1 ADT 16 (18)
ADT only 4 (4)
*Values are reported as numbers of patients, with percentages
of patients in parentheses, unless otherwise indicated.
†Values in parentheses are interquartile ranges.
RTX 5 treatment.
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Management Impact
Treating investigators reported that 18F-FCH imaging changed
planned management in 46% of men (42/91), whereas pelvic MRI
changed expected management in 24% (21/88) (P , 0.003). With
18F-FCH, an expected increase in the radiation field size or dose
occurred in 23% (21/91), ADT was added in 8% (7/91), a biopsy
was done in 9% (8/91), and a reported deescalation to no planned
treatment occurred in 10% (9/91). PSMA added an additional
management change over that of 18F-FCH in 23% of men (7/31).
After the completion of imaging (18F-FCH, pelvic MRI, and
PSMA), the actual treatment administered differed from that
planned before imaging in 47% of men enrolled (43/91). Although
the expected treatment in all men before imaging was SRT, this plan
changed to no treatment in 21% (19/91), an increase in the radiation
field or dose in 9% (8/91), and the addition of ADT in 22% (20/91).
Overall, 53% (48/91) had negative scans with all available imaging
modalities. In men with negative scans, actual management changed
from SRT to no treatment in 23% (11/48), whereas the remainder
underwent SRT (33/48 had SRT of the fossa only, 4/48 had SRT of
the fossa plus nodes, and 5/48 had SRT plus ADT).
Treatment Response
Men given ADT (22% [20/91]) were excluded from the
response assessment, as were 21% (19/91) of the men who received
no treatment. The remaining 57% (52/91) underwent SRT without
ADT. The overall treatment response among the patients treated
with radiotherapy only (SRT or SRT1N [N 5 nodes]) was 67%
(35/52). The treatment responses to SRT were higher in men with
negative scans or scans showing disease confined to the PF than in
those with extra-PF disease: 70% (32/46) versus 50% (2/4) with
pelvic MRI (P 5 0.45), 75% (32/43) versus 33% (3/9) with 18F-
FCH (P, 0.02), and 88% (7/8) versus 14% (1/7) with PSMA (P,
0.005) (Fig. 3).
For men who had negative results with all 3 imaging modalities
(43% [43/71]), SRT resulted in a significant treatment response in
78% (25/32), compared with only 9% of men (1/11) who did not
receive SRT (P , 0.0005).
DISCUSSION
PF SRT is the current standard of care in men with biochemical
failure after RP. At this time, it remains the last chance for cure in
these men, with about half of men achieving a complete bio-
chemical response at 5 y after SRT (2,3,6).This chance of cure is
significantly lower in men with high-risk features on clinical risk
nomograms, dropping to as low as 18% in men with rapid PSA
doubling times and high Gleason scores (4,6). Conventional imaging
has a low sensitivity for detecting sites of recurrent disease at times
when salvage therapies are most likely to be successful (PSA levels
of,1–2 ng/mL) (7). It is not clear whether complex imaging in men
with a high risk of BCR can improve the prediction of which men
will benefit from SRT or which imaging modality is optimal. Ideally,
imaging at the time of biochemical failure after RP would identify
men who would achieve the most benefit from SRT, maximizing the
chance of a long-term response.
The major findings of the present study were that the PET tracer
agents had a higher detection rate for prostate cancer that had
spread beyond the PF than pelvic MRI. Further, men with negative
scans or those with disease confined to the PF on PET (PMSA or
18F-FCH) exhibited higher SRT response rates, suggesting the
successful identification of men most likely to benefit from fossa-
only radiotherapy.
To our knowledge, this is the first study that has undertaken a
direct prospective comparison of 3 imaging modalities now
frequently used in the assessment of BCR after RP, in the presence
of negative or equivocal conventional imaging results. The
combination of all modalities identified disease recurrence in
about half of the men for whom conventional imaging had not
been helpful. However, there were significant variations in
detection rates with the imaging modalities undertaken concur-
rently in the present study. MRI and PSMA had the highest levels
of identification of disease confined to the fossa. PET (18F-FCH
and PSMA) had significantly higher detection rates for disease
outside the PF than MRI, with an associated overall higher
sensitivity.
With the exception of the recent Australian guidelines (8), most
currently published guidelines do not recommend imaging for
BCR at PSA levels of less than 1.0 ng/mL (7). This stance has
been challenged recently, with several studies reporting high de-
tection rates for recurrent disease in men with BCR at low PSA
levels using PSMA PET (9–14).The present study confirmed the
high detection rates for disease recurrence using PSMA both in the
TABLE 2
Per-Patient Detection Rates for PF Disease and Extra-PF








Pelvic MRI 19/88 (21.5) 7/88 (8) 25/88 (28)
18F-FCH 12/91 (13) 17/91 (19) 29/91 (32)
PSMA 6/31 (19) 10/31 (32) 13/31 (42)
Overall 27/91 (30) 21/91 (23) 43/91 (47)
*Data are reported as numbers of patients, with percentages of
patients in parentheses.
TABLE 3
Per-Patient Comparisons of 18F-FCH and MRI and of














Extra-PF disease 2 5 7






Extra-PF disease 1 9 10
Total 21 10 31
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PF and distantly. Consistent with the previous comparisons of
18F-FCH and PSMA PET, the number of extra fossa lesions visu-
alized on PSMA was higher than that visualized on 18F-FCH in
men who underwent imaging with both modalities (15,16). How-
ever, the difference in detection rates for 18F-FCH and PSMAwas
not as high as that reported previously, likely because of the high-
risk nature of the patient cohort in the present study. 18F-FCH
performs better with more aggressive prostate cancer phenotypes
(shorter doubling time or higher-grade disease) at low PSA levels
(17). The men enrolled in the present study had high-risk features
and a high likelihood of a poor response to SRT. We found that the
detection rate for 18F-FCH in our patient cohort—despite a low
median PSA level (0.42 ng/mL)—was substantial (32%), with more
than half of the sites being extra-PF.
The use of pelvic MRI to better target or boost radiotherapy
fields in the setting of BCR is appealing (18,19). However, few
data on the detection rate for or the utility of pelvic MRI in the
setting of BCR at PSA levels at which men are still curable have
been published (20–22). A retrospective review of 473 men who
underwent pelvic MRI before SRT for BCR found that up to 57%
of men had positive MRI results, 49% of recurrences were local,
and 8% of recurrences were distant to the fossa (21). The present
study also showed that pelvic MRI detected predominantly local
PF recurrences, with a low detection rate for pelvic nodal disease.
Further, we found that a significant proportion of men with neg-
ative or fossa-confined MRI scan results had pelvic nodal or dis-
tant disease that was identified on PSMA or 18F-FCH. Most of
these recurrences identified by PET alone occurred within regional
pelvic nodes, within the field of view of a pelvic MRI study. These
data suggest that although pelvic MRI may
be useful in helping to plan radiotherapy
fields and boosting the detection of sites of
recurrence in the fossa, it is less helpful in
determining whether SRT will be success-
ful and therefore should be used as an ad-
junct to PET imaging, not in isolation.
The high rates of extra-PF disease iden-
tified on 18F-FCH led to a consequent high
management impact (46%). Treating investi-
gators reported an additional 23% manage-
ment impact of PSMA above and beyond
that of 18F-FCH in the subgroup of men
who underwent both types of imaging, sug-
gesting the higher potential of PSMA PET
even in this high-risk patient population.
MRI had a significantly lower management
impact (23%), likely because of the rela-
tively lower level of detection of extra-PF
disease by MRI than by PET. Management
changes predominantly involved changing
radiotherapy fields or adding systemic ADT.
However, an unexpected management
impact was that a significant proportion of
men had a deescalation of treatment, with
21% of men not undergoing their intended
SRT or any other systemic treatments. Most
men who did not receive planned SRT had
negative scans for all modalities. Most men
who had negative scans and did not undergo
further systemic or targeted treatments over
the course of the trial had consequent increases in PSA levels to
greater than (potentially) curative levels (92%). The significant in-
creases in PSA levels in these men contrast starkly with the high
PSA responses in men who had negative scans and were treated
with SRT. As an imaging study, the present study enrolled men who
were eligible for and planned to have SRT but did not dictate final
treatment. The substantial response rates among men with negative
imaging results and receiving SRT suggest that SRT should still be
considered. The negative imaging results likely reflect the presence
of micrometastatic disease that is still confined to the PF and that
would be optimally managed with targeted treatment.
All men enrolled in the present study had clinical characteristics
previously associated with a poor biochemical response to SRT,
presumably because of disease located outside the fossa—which
would not be controlled by local treatment and which, until
FIGURE 2. Man with a rising PSA (0.29 ng/mL) 5 y after RP. Imaging demonstrates PF recur-
rence on PSMA (A), MRI (B), and 18F-FCH (C). Solitary PSMA-avid (D), 18F-FCH (E) and MRI-
negative focus in thoracic spine (red arrow) was confirmed as true-positive (repeat imaging and
targeted treatment response).
TABLE 4
Per-Patient Diagnostic Accuracies of Imaging Modalities for
Extra-PF Prostate Cancer in Men with BCR After RP and












Pelvic MRI 19 97 66 80
18F-FCH 47.8 97 73.9 91.7
PSMA 66.67 100 50 100
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recently, we could not accurately identify. The finding of disease
outside the PF by both PSMA and 18F-FCH could predict whether
a patient will have a treatment response to SRT. This ability to
stratify men into high and low treatment responses was demon-
strated most strongly with PSMA. Men with negative results or
fossa-confined disease on PSMA had an 88% treatment re-
sponse to fossa SRT, compared with just 14% in men with ex-
tra-PF sites of disease on PSMA. This ability of PSMA to
effectively stratify patients who will have a significant treatment
response to SRT in the setting of biochemical failure was previ-
ously demonstrated, but not in such a high-risk cohort or in com-
parison to both 18F-FCH and pelvic MRI (11). The ongoing
follow-up for up to 3 y after SRT in these men will be important
in determining whether this early treatment response remains clin-
ically significant.
Only a subset of men (31/91) were able to undergo PSMA in
addition to 18F-FCH because of different availabilities of the tracer
across continents. All PSMA studies were undertaken in the 4 sites
within Australia where enrolled men underwent MRI, 18F-FCH,
and PSMA within the study time frame. The limited number of
men undergoing all 3 imaging modalities restricted the ability of
the study to lead to strong conclusions about the relative benefits
of 18F-FCH or PSMA in this patient cohort.
In this initial study, treatment response rather than biochemical
failure at 3 y was assessed. Furthermore, a significant number of
men on ADT at the time of their radiotherapy were not included in
the treatment response analysis. Data collection is ongoing with
the study, with a view to evaluating 3-y biochemical failure rates
after SRT, rather than the currently reported treatment response;
men who were treated with short-term ADT around the time of
SRT will be included.
A further limitation of the present study was the proportion of
men who had negative imaging results and did not undergo
subsequent treatment with SRT. The study did not mandate SRT
in men with negative results or fossa-confined disease on trial
imaging; however, planned SRT was a trial inclusion criterion, so
the deescalation of therapy in this subset of men was unexpected.
Although this development diminished the ability of the study to
evaluate the benefit of imaging in identifying men who will have a
treatment response to SRT, it served to highlight the benefit that
treatment with SRT affords in men with negative scans.
In the present study, the detection rate for pelvic MRI was
compared with that for whole-body imaging with PSMA or 18F-
FCH. The lower detection rate for pelvic MRI may be explained, at
least in part, by the limited field of view of pelvic MRI compared
with that of whole-body PET. However, a separate analysis of metastatic
foci within the field of view of pelvic MRI confirmed that the MRI
detection rate for pelvic lymph nodes was significantly lower than
that of either 18F-FCH or PSMA. This finding was important for
the patient cohort, in whom more than 80% of extra-PF disease
was nodal.
CONCLUSION
Both 18F-FCH PET and PSMA PET had high detection rates for
extra-PF disease in men with a high risk of BCR after RP and
negative/equivocal conventional imaging results. The impact on
management and the higher therapy treatment responses among
men with negative results or PF-confined disease on PET sug-
gested an important role for PET in triaging men being considered
for curative SRT.
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